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This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e17 (https://www.
gastrojournal.org/cme/home). Learning Objective: Upon completion of this CME activity, successful learners will be able to (1)
discuss the clinical relevance of normalizing serum albumin concentration in patients with decompensated cirrhosis and ascites
and (2) identify the main mechanisms of action of albumin in this setting.Effects of long-term albumin treatment on serum albumin levels and inflammatory cytokines
High albumin dose (HAlbD: 1.5 g/kg every week, blue figures) but not low albumin dose (LAlbD: 1 g/kg every 2 weeks:
red figures) normalized serum albumin levels and decreased inflammatory cytokines
WHAT YOU NEED TO KNOW
BACKGROUND & CONTEXT
Systemic inflammation is an important issue in acute
decompensation of cirrhosis, this is thought to play a
major role in the pathophysiology of complications,
including multiple organ failure.
NEW FINDINGS
Long-term high albumin treatment (1.5 g/kg every week
for 12 weeks) showed significant immunomodulatory
effects in an exploratory cohort of patients with
decompensated cirrhosis. This finding was validated in a
short-term (7 days) investigation in patients with
infections.
LIMITATIONS
Low number of patients included in the investigation
cohort.
IMPACT
Albumin treatment improves markers of systemic
inflammation in patients with decompensated cirrhosis.
This effect may underlie the beneficial effects of albumin
therapy on clinical outcomes in this setting.
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LIVERBACKGROUND & AIMS: We investigated the effect of albumin
treatment (20% solution) on hypoalbuminemia, car-
diocirculatory dysfunction, portal hypertension, and systemic
inflammation in patients with decompensated cirrhosis with
and without bacterial infections. METHODS: We performed a
prospective study to assess the effects of long-term (12 weeks)
treatment with low doses (1 g/kg body weight every 2 weeks)
and high doses (1.5 g/kg every week) of albumin on serum
albumin, plasma renin, cardiocirculatory function, portal pres-
sure, and plasma levels of cytokines, collecting data from 18
patients without bacterial infections (the Pilot-PRECIOSA
study). We also assessed the effect of short-term (1 week)
treatment with antibiotics alone vs the combination of albumin
plus antibiotics (1.5 g/kg on day 1 and 1 g/kg on day 3) on
plasma levels of cytokines in biobanked samples from 78 pa-
tients with bacterial infections included in a randomized
controlled trial (INFECIR-2 study). RESULTS: Circulatory
dysfunction and systemic inflammation were extremely unsta-
ble in many patients included in the Pilot-PRECIOSA study;
these patients had intense and reversible peaks in plasma
levels of renin and interleukin 6. Long-term high-dose albumin,
but not low-dose albumin, was associated with normalization of
serum level of albumin, improved stability of the circulation
and left ventricular function, and reduced plasma levels of cy-
tokines (interleukin 6, granulocyte colony-stimulating factor,
interleukin 1 receptor antagonist, and vascular endothelial
growth factor) without significant changes in portal pressure.
The immune-modulatory effects of albumin observed in the
Pilot-PRECIOSA study were confirmed in the INFECIR-2 study.
In this study, patients given albumin had significant reductions
in plasma levels of cytokines. CONCLUSIONS: In an analysis of
data from 2 trials (Pilot-PRECIOSA study and INFECIR-2 study),
we found that albumin treatment reduced systemic inflamma-
tion and cardiocirculatory dysfunction in patients with
decompensated cirrhosis. These effects might be responsible
for the beneficial effects of albumin therapy on outcomes of
patients with decompensated cirrhosis. ClinicalTrials.gov,
Numbers: NCT00968695 and NCT03451292.* Authors share co-first authorship.Keywords: Liver-Related Complications; Immune Response;
Splanchnic Hemodynamics; Interventional Trials.
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Liver Failure Consortium; ELISA, enzyme-linked immunosorbent assay;
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INFECIR, albumin administration in the prevention of hepatorenal syn-
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0016-5085
https://doi.org/10.1053/j.gastro.2019.03.021Ttreatment in cirrhosis were performed in the 1980s
and consisted of several randomized controlled trials
(RCTs) showing that paracentesis was a rapid, effective, and
safe therapy of ascites if performed with intravenous albu-
min administration (8 g/L of ascitic fluid removed).1 Sort
et al2 subsequently showed that treatment of spontaneous
bacterial peritonitis (SBP) with antibiotics plus albumin (1.5
g/kg body weight at infection diagnosis and 1 g/kg on day
3) was associated with a 60% reduction in the prevalence of
type 1 hepatorenal syndrome (HRS), a special form of acute-
on-chronic liver failure (ACLF), and in hospital mortality.
Ortega et al3 later showed that the simultaneous adminis-
tration of terlipressin and albumin (20–40 g/d for 7–14
days) normalized serum creatinine concentration in
approximately 50% of patients with HRS) Finally, theANSWER study recently showed that long-term (18 months)
prophylactic administration of albumin (40 g every week) to
patients with prior history of ascites is highly effective in
preventing follow-up development of new episodes of as-
cites, refractory ascites, HRS, hepatic encephalopathy, and
bacterial infections, reducing hospital admissions and
improving survival.4 This successful research activity on the
therapeutic use of albumin in cirrhosis contrasts sharply
with the low number of investigations performed on its
mechanisms of action.1
This article reports the results of the Pilot-PRECIOSA
study, which aimed to identify an albumin dosage that
normalizes serum albumin concentration and investigate
the effects of the administration of this albumin dosage for
12 weeks on hypoalbuminemia, cardiocirculatory hemody-
namics, effective blood volume, portal pressure, and sys-
temic inflammation (as estimated by the plasma levels of
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ERinterleukin [IL] 6) in 18 patients with decompensated
cirrhosis.
Recent investigations have suggested that systemic
inflammation plays a major role in the pathogenesis of acute
decompensation and ACLF in cirrhosis.5 The observation of
a marked suppression of the plasma levels of IL-6 during
albumin treatment in the Pilot-PRECIOSA STUDY, which
suggests an immunomodulatory effect of albumin treat-
ment, prompted us to perform additional investigations to
confirm this feature. These investigations consisted of the
measurement of a large panel of inflammatory mediators in
biobanking material from the Pilot-PRECIOSA study and
from the INFECIR-2 study, a RCT aimed at comparing the
efficacy of antibiotics alone vs albumin plus antibiotics in
patients with decompensated cirrhosis and bacterial infec-






The Pilot-PRECIOSA study and the INFECIR-2 study were
approved by the corresponding ethics committees of each
hospital involved. The informed consent forms of the 2 studies
included the potential use of biobanking material for measuring
serum albumin levels and plasma renin and cytokine
concentrations.The Pilot-PRECIOSA Study
The Pilot-PRECIOSA study (IG0802, registered at
ClinicalTrials.gov as NCT00968695) is a proof-of-concept,
open-label, multicenter, nonrandomized (single-group), pro-
spective, phase 4 safety and dosage exploratory investigation
sponsored by Grifols with the aim of getting preliminary
information to design a currently ongoing multicenter, ran-
domized, controlled therapeutic trial to assess the efficacy of
long-term (1 year) albumin treatment in the prevention of
ACLF and mortality in decompensated cirrhosis (PRECIOSA
study, ClinicalTrials.gov number NCT03451292).
Investigators of the European Association for the Study of the
Liver–Chronic Liver Failure (EASL-CLIF) Consortium from 3
hospitals (Hospital Clinic and Hospital de Sant Pau in Barcelona
and Hospital Ramón y Cajal in Madrid, Spain) participated in the
design and implementation of the study, which started in July
2009 and was completed in April 2014. These hospitals use the
same methodology for cardiocirculatory and hepatic hemody-
namic studies and have extensive experience in cooperative
hemodynamic, pathophysiological, and therapeutic studies.
Nonstandard laboratory measurements (hormones and bio-
markers estimating systemic inflammation) were centralized at
the Hospital Clinic. The results of the Pilot-PRECIOSA study were
submitted to embargo until the start of the PRECIOSA study.
Inclusion and Exclusion Criteria and Patients
Evaluated. The study enrolled noninfected patients with
decompensated cirrhosis and severe circulatory dysfunction as
defined by the presence of ascites, renal dysfunction (serum
creatinine  1.2 mg/dL or blood urea nitrogen  25 mg/dL or
dilutional hyponatremia [serum sodium  130 mEq/L]), high
levels of plasma renin activity (PRA) ( 2 ng/mL$h), and need
for diuretic treatment to prevent ascites recurrence (at least
200 mg of spironolactone or 100 mg of spironolactone and 40mg of furosemide). PRA was used to assess sequential changes
in effective arterial blood volume. The exclusion criteria are
detailed in the Supplementary Materials.
A total of 135 patients were evaluated; 72 were eligible, and
among these, 39 were excluded based on the exclusion criteria.
Of the 33 remaining patients, 12 were excluded for data anal-
ysis due to (1) lack of abnormal PRA value (<2 ng/mL$h) at
enrollment (2 patients), (2) development of complications
requiring treatment that interfered with the interpretations of
the results (intensive care, liver transplantation, and insertion
of a transjugular intrahepatic portosystemic shunt) (3 patients),
and (3) discontinuation of albumin treatment (7 patients).
Three of the remaining 21 patients died within the study
period, and 3 did not give informed consent for car-
diocirculatory and hepatic hemodynamic assessment. The
clinical characteristics at enrollment and the main complica-
tions and causes of death during the study period are presented
in Supplementary Table 1.
Chronogram. Day 0. Samples were obtained for stan-
dard laboratory tests, serum albumin concentration, PRA (as
a marker of effective blood volume), plasma concentrations
of atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP) (markers of central blood volume expansion),
and IL-6, followed by the hepatic and cardiocirculatory he-
modynamic study. The methods for these studies have been
previously described (Supplementary Table 2).7 Immediately
afterward, patients received the first albumin dose, and they
were followed up for 20 weeks.
Weeks 1–12. The first 10 patients received an albumin
dose of 1g/kg body weight every 2 weeks for 12 weeks (a total
of 7 albumin treatments). PRA was measured every 2 weeks
before each albumin dose in the first 5 patients and ad hoc
weekly in the remaining 5 patients. Plasma IL-6 and serum
albumin concentrations were measured every 2 weeks. An
interim analysis in these first 10 patients showed that this dose
of albumin was insufficient to normalize serum albumin con-
centration throughout the last 10 weeks of the study period in
most patients (normal serum albumin concentration, 34–47 g/
L). Accordingly, albumin dosage was increased to 1.5 g/kg body
weight every week in the remaining patients. Therefore, this
second group of patients received a higher albumin dosage per
treatment and more albumin treatments (13) within the same
time period (on day 0 and then every week for 12 weeks).
Samples for PRA were taken ad hoc weekly during treatment.
Samples for serum concentration of albumin and plasma levels
of IL-6 were obtained every 2 weeks. For the description of the
results, the group of patients who received albumin at a dose of
1g/kg every 2 weeks was defined as the low albumin dosage
(LAlbD) group and that receiving albumin at a dose of 1.5 g/kg
every week as the high albumin dosage (HAlbD) group.
Week 14. Two weeks after the last albumin dose, the
cardiopulmonary and hepatic hemodynamic study was
repeated.
Post Hoc Measurements of Cytokines, Chemo-
kines, and Other Inflammatory Markers. The post hoc
assessment of the effects of albumin treatment on systemic
inflammation was performed by assessing a large panel of in-
flammatory mediators and biomarkers, including 24 cytokines, 10
chemokines, 4 growth factors, and 6 markers of endothelial
dysfunction (2), coagulation/platelet dysfunction (2), and mono-
cyte activation (2), in biobanking material (September 2018).
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The INFECIR-2 study is an EASL-CLIF Consortium
investigator-promoted, phase 4, randomized, open-label, par-
allel, multicenter trial promoted by the Fundació Clínic (Hos-
pital Clínic, University of Barcelona, Spain). It began in
September 2014 and was finished in December 2016
(ClinicalTrials.gov number NCT02034279). The inclusion and
exclusion criteria are detailed in the Supplementary Materials.
The study aimed to assess the efficacy of short-term albumin
treatment in the prevention of ACLF and hospital mortality in
136 patients with decompensated cirrhosis and acute bacterial
infections unrelated to SBP. Eighteen patients were considered
to have been erroneously included. Therefore, 118 patients
were randomly assigned to receive either antibiotics alone
(antibiotics-alone group, n ¼ 57), or antibiotics plus 2 albumin
doses (ie, 1.5 g/kg at inclusion [day 1] and 1 g/kg on day 3)
(albumin-plus-antibiotics group, n ¼ 61). Plasma samples for
biobanking were obtained on day 1, before the administration
of the first albumin dose; on day 3, before the second albumin
dose; and/or on day 7 in 48 patients from the albumin-plus-
antibiotics group and 47 patients from the antibiotics-alone
group. “On-treatment” values of plasma cytokine levels given
in the article represent the average of those obtained on days 3
and 7 (in patients with 2 measurements) or those obtained on
day 3 or 7 in patients with only a single measurement. Both
groups were similar regarding patient characteristics (except
for the combined prevalence of ACLF and kidney dysfunction at
baseline, which was higher in the albumin arm), type of infec-
tion, and antibiotic therapy. The results of the INFECIR-2 study
have recently been reported.6
The current study used biobanking aliquots from the
INFECIR-2 study for measurement of the serum concentration
of albumin, the plasma concentration of renin (PRC), and the
plasma concentrations of the same panel of cytokines, chemo-
kines, growth factors, and other inflammatory markers studied
in the Pilot-PRECIOSA study. Measurements were performed at
baseline and during treatment among 40 patients from the
antibiotics-alone group and 38 patients from the albumin-plus-
antibiotics group. The prespecified criteria to select these 78
patients were (1) availability of biobanking samples, (2)
infection receiving appropriate empirical antibiotic treatment
(3) absence of severe complications within the first week of
treatment that could affect the interpretation of the results, and
(4) completion of 1 week of follow-up.
Laboratory Methods
Hormones and IL-6 were measured by radioimmunoassay
(PRA), chemiluminescent immunoassay (PRC), immunoassay
(ANP and BNP), and enzyme-linked immunosorbent assay
(ELISA) (IL-6). Measurement of the panel of cytokines, che-
mokines, and other inflammatory mediators in patients from
the Pilot-PRECIOSA and INFECIR-2 studies were performed by
using 2 multiplex immunoassays based on Luminex multi-
analyte profiling technology (Luminex Corp, Austin, TX). The
plasma levels of sCD163 and sMR/sCD206 were determined by
ELISA. Methods are detailed in the Supplementary Materials.
Statistical Methods
In the Pilot-PRECIOSA study, for a given patient receiving
albumin treatment, there were several available results forserum albumin, PRA, and plasma IL-6. We averaged all the
available values within the last 10 weeks of treatment to obtain
a single on-treatment value for comparison with the corre-
sponding baseline value.
Results are presented as median and interquartile range. For
univariate analysis, Mann-Whitney test and Wilcoxon signed rank
test were used for non-normally distributed variables. In all sta-
tistical analyses, significance was set at P < .05. Analyses were
performedwith SAS, version 9.4 (SAS Institute, Cary, NC) statistical
packages. Graphs were performed with GraphPad Prism, version
5.00 (GraphPad Software, San Diego, CA).Results
Baseline Clinical Characteristics of the Patients
Included in the Pilot-PRECIOSA Study
All of the 18 patients included were admitted to the
hospital for the treatment of ascites; 3 had diabetes mellitus,
1 had hepatocellular carcinoma, and 2 had minimal hepatic
encephalopathy. Other characteristics at enrollment are
presented in Supplementary Table 1.Effect of Long-Term Albumin Treatment and Its
Dosage on Serum Albumin Concentration (Pilot-
PRECIOSA Study)
Thirteen out of the 18 patients includedwho completed the
sequential measurement of plasma albumin concentration had
baseline hypoalbuminemia (serum albumin concentration <
34 g/L). The effect of albumin treatment on serum albumin
concentration was related to 2 factors. The first factor was al-
bumin dosage. Although patients of the LAlbD group with
baseline hypoalbuminemia (n ¼ 7) exhibited increases in
serum levels of albumin during treatment, only 1 achieved
normalized the serum albumin concentration, that is, had an
increase in albumin level to a value 34 g/L in all measure-
ments. In contrast, all patients of theHAlbDgroupwithbaseline
hypoalbuminemia (n ¼ 6) achieved on-treatment normalized
serum albumin concentration (P < .001) Figure 1A). The me-
dian increases in serum albumin among patients receiving
HAlbD or LAlbD are detailed in Table 1 for all patients and in
Figure 1B specifically for patients with baseline hypo-
albuminemia. Four of the 5 patients with normal baseline
serum albumin concentration (3 from the LAlbD group and 2
fromtheHAlbDgroup) showedrelatively stable serumalbumin
concentration (always within the normal limits of 34–47 g/L)
throughout the study (Figure 1C). The fifth patient exhibited an
on-treatment increase in serum albumin, but this was also
within normal limits.
The second factor influencing the effect of albumin
treatment was hypoalbuminemia grade at baseline. There
was a significant inverse correlation between the baseline
serum albumin concentration and the median change in
serum albumin during treatment in both the HAlbD and the
LAlbD groups (Figure 1D): the lower the baseline albumin
concentration, the higher the median increase in the serum
albumin levels achieved during treatment. The response to
albumin treatment at each level of serum albumin concen-
tration was higher in patients receiving HAlbD.








Effect of Long-Term Albumin Treatment and Its
Dosage on Plasma Renin Activity (Pilot-
PRECIOSA Study)
Long-term albumin treatment was not associated with sig-
nificant suppression in PRA in patients receiving HAlbD or
LAlbD, suggesting a minor effect on the effective blood volume
(Table 1). Figure 1E and F shows the individual time-course
changes of PRA in patients receiving LAlbD and HAlbD,
respectively. An intriguing observation was the extreme insta-
bilityof effectivebloodvolume,as indicatedby thedevelopment
of acute, high, and transient positive peaks of PRA (increase in
PRA>100%to levels over10ng/mL$h) in a significant number
of patients. Peaks were observed more frequently in the LAlbD
group (6 patients, 60%) than in the HAlbD group (1 patient,
12.5%) (P ¼ .04), suggesting that although albumin treatment
was not effective in improving mean effective blood volume, it
was capable of stabilizing circulatory function.
Effect of Long-Term Albumin Treatment and Its
Dosage on Plasma Interleukin 6 Levels (Pilot-
PRECIOSA Study)
To explore the possibility that albumin treatment can affect
systemic inflammation, we sequentially measured the plasma
levels of IL-6 onday0 andevery2weeks after day0 in the Pilot-
PRECIOSA study. IL-6 is a paradigmatic proinflammatory
cytokine whose plasma levels are increased in most patients
with cirrhosis and systemic inflammation.5 Nine patients from
the LAlbD group and 7 from the HAlbD group had measurable
levels of IL-6 at baseline and during treatment. The effect of
albumin treatment on systemic inflammation in each patient
could then be estimated as the absolute or percent change of IL-
6 betweenbaseline value andon-treatment value (Table 1). The
median baseline value for plasma IL-6 levels in the 16 patients
was well above the normal range, consistent with the existence
of systemic inflammation in this group of patients. We arbi-
trarily defined a patient as having developed significant
immunomodulatory response to albumin treatment when the
on-treatment IL-6 level decreasedbymore than20%below the
baseline level. An outstanding finding of the current study was
that the majority of patients receiving HAlbD (6 of 7 patients,
85.7%)butonly1of9patients receivingLAlbD(11%) (P¼ .003
for between-group comparison) had a reduction of plasma IL-6
of>20%, suggesting that long-term treatment with HAlbD, but
not with LAlbD, induces significant immunomodulatory effects
inpatientswithdecompensated cirrhosis. Consistentwith these
findings, we found that the median reduction from baseline for
IL-6 was significantly greater among patients receiving HAlbD
than among those receiving LAlbD, whether reduction was
expressed by percentage or absolute values (Table 1).
A second important finding was that systemic inflam-
mation was unstable in a significant number of patients (1
of 7 receiving HAlbD and 4 of 9 receiving LAlbD), with acute,
high, and reversible peaks of the plasma IL-6 (ie, increases
by at least 100% to levels over 100 pg/mL) during albumin
treatment (Figure 2A). The remaining 11 patients showed
small changes (mainly patients receiving LAlbD) or marked
reductions (mainly patients receiving HAlbD) of on-
treatment IL-6 (Figure 2B).Effect of Long-Term Albumin Treatment and Its
Dosage on a Large Panel of Plasma Cytokines
(Pilot-PRECIOSA Study)
The finding that elevated baseline plasma IL-6 levels, as
determined by ELISA, can be reduced by albumin therapy in
a dose-dependent manner prompted us to investigate the
effects of this treatment on the plasma levels of a large
number of cytokines (n ¼ 24) in biobanking samples ob-
tained at baseline and at week 6 of albumin treatment in 10
patients from the LAlbD group and 5 patients from the
HAlbD group. In addition, we measured the plasma levels of
the 24 cytokines in 25 healthy donors recruited at the
Hospital Clínic Blood Bank.
Among the 24 cytokinesmeasured, 11were not detectable
in any patient/healthy individual. Baseline values of all but 2
of the remaining 13 cytokines included in the panel were
significantly higher among patients with decompensated
cirrhosis than among healthy individuals, confirming the ex-
istence of full-blown systemic inflammation in decom-
pensated cirrhosis (Table 2). In the next tables, only changes
in relevant cytokines are presented. Patients receiving LAlbD
experienced only a small reduction or moderate increase
during treatment in the plasma levels of these cytokines, a
feature that contrasts sharply with themarked suppression of
most cytokines in patients receiving HAlbD (Table 3 and
Figure 2C and D). These results strongly suggest that long-
term albumin treatment, if given at high dosage, has a sig-
nificant immunomodulatory effect in decompensated
cirrhosis, reducing the degree of systemic inflammation.
Effects of Long-Term Albumin Treatment on
Systemic and Splanchnic Hemodynamics,
Natriuretic Peptides, and Liver and Renal
Function (Pilot-PRECIOSA study)
Treatment with HAlbD, but not with LAlbD, was associated
with a significant increase in cardiac index, systolic volume,
and left ventricular (LV) stroke work index, indicating an in-
crease in LV function (Table 4). Therewere no changes inmost
parameters estimating cardiac preload, including atrial pres-
sure, pulmonary capillary wedged pressure, and plasma con-
centrations of ANP and BNP. There was, however, a significant
increase in mean pulmonary artery pressure in patients
receiving HAlbD, although it might be related to improvement
in right ventricular function. All patients had severe portal
hypertension at enrollment. HAlbD and LAlbD treatment,
however, was not associated with significant changes in he-
patic venous pressure gradient, a sensitive marker of portal
pressure. There were also no major changes in other relevant
standard laboratory parameters in either group.
Effect of Short-Term Albumin Treatment on
Serum Albumin and Plasma Levels of Renin and
of a Large Panel of Inflammatory Cytokines in
Patients With Infections (INFECIR-2 Study)
Next, we asked whether albumin therapy could have a
reducing effect on plasma cytokine levels in patients with
bacterial infections included in the INFECIR-2 study.
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of the systemic inflammation already present in patients
with decompensated cirrhosis.5,7 This explains why baseline
levels of tumor necrosis factor a, IL-4, IL-6, and IL-10 were
significantly higher among patients included in the INFECIR-
2 study than among those included in the Pilot-PRECIOSA
study (Table 2). As expected for a randomized trial, in the
INFECIR-2 study, the baseline plasma cytokine levels were
similar among patients assigned to receive antibiotics aloneand among those assigned to receive albumin plus antibi-
otics (Table 5).
Treatment with antibiotics alone was not associated
with significant changes in most cytokines. Only 1 patient
showed a significant suppression (tumor necrosis factor a)
during treatment. In contrast, patients treated with albumin
plus antibiotics had, during treatment, a significant decrease
or a clear trend for a reduction in most cytokines (Table 5),
suggesting that albumin associated with antibiotics was
Table 1.Serum Albumin, PRA, and Plasma Levels of IL-6 at Baseline and During Albumin Treatment in 18 Patients With
Decompensated Cirrhosis Unrelated to Bacterial Infection Who Were Enrolled in the Pilot-PRECIOSA Study and









Baseline, g/L 27.6 (22.7 to 34.0) 26.5 (24.8 to 40.3) .83
On-treatment average value, g/L 39.2 (38.7 to 43.0)b 33.3 (31.8 to 37.9)c .004
Absolute change, g/L 12.7 (8.5 to 16.6)b 5.7 (–1.8 to 8.0)c .01
Percent change, % 48.7 (26.7 to 71.3)b 20.2 (–4.1 to 32.5)c .04
Plasma renin activity
Baseline, ng/mL$h 5.5 (3.6 to 7.9) 7.9 (3.8 to 12.3) .41
On-treatment average value, ng/mL$h 4.9 (3.9 to 5.8) 6.9 (3.8 to 11.3) .17
Absolute change, ng/mL 0.2 (–4.2 to 1.3) –0.4 (–5.5 to 5.8) .64
Percent change, % 2.0 (–44.4 to 36.2) –6.7 (–45.3 to 146.2) .69
Plasma IL-6 concentration
Baseline, pg/mL 123.5 (51.5 to 151.5) 41.5 (25.8 to 75.0) .02
On-treatment average value, pg/mL 62.5 (24.5 to 93.6)b 57.5 (30.0 to 79.2) .76
Absolute change, pg/mL –53.0 (–108.0 to –18.0)b –3.2 (–11.1 to 30.0) .04
Percent change, % –56.0 (–68.8 to –24.2)b –7.6 (–15.7 to 79.7) .04
NOTE. Values are reported as median (interquartile range). For each variable in each patient, the average value during
treatment was obtained by using all on-treatment values of this variable available.
aP value for the between-group comparison. Values in bold indicate P < .05.
bP < .05 for the within-group comparison with baseline values.
cP ¼ .05 for the within-group comparison with baseline values.








more effective than antibiotics alone in attenuating baseline
systemic inflammation in patients with bacterial infections.
In the INFECIR-2 study, baseline values for serum al-
bumin concentration were similar between patients of the
antibiotics-alone group (26 [20–30] g/L) and those of the
albumin-plus-antibiotics group (25 [19–30] g/L) (P ¼ .91).
The baseline activity of the renin-angiotensin system, esti-
mated by PRC, was greater among patients in the albumin-
plus-antibiotics group than among those in the antibiotics-
alone group, although the difference was not statistically
significant (241.6 [46.3–903.0] mIU/mL and 125.0 [34.0–
398.6] mIU/mL, respectively; P ¼ .25). Antibiotics alone
were not associated with significant changes from baseline
for serum albumin concentration (0 [–20 to 1.0] g/L) or PRC=
Figure 1. Changes in serum albumin concentration and PRA in
LAlbD (red color) in the 18 patients included in the Pilot-PREC
centration among the 13 patients with baseline hypoalbuminemi
indicate the upper and lower normal limits of serum albumin
developed a rapid increase (within 2 weeks) in serum albumin c
remaining 10 weeks of the study. In contrast, although all 7 pat
increased serum levels of albumin during treatment, only 1 nor
influenced the response to albumin treatment. (B) The first factor
hypoalbuminemia, the individual absolute median increase in ser
those receiving LAlbD. (C) The second factor was the feedback
influences the hepatic synthesis of albumin. In most patients w
albumin prevented the increase in the serum concentration of a
feedback mechanism was also reflected by the close inverse c
and the mean increase in serum albumin during treatment. Th
absolute mean increase in the serum concentration of albu
dysfunction was extremely unstable during albumin treatment in
(F) Circulatory instability was significantly improved in patients r
throughout treatment.(–1.2 [–26.5 to 129.6] mIU/mL). In contrast, albumin-plus-
antibiotics treatment significantly increased serum albu-
min concentration (7.0 [4.0–10.0] g/L, P < .0001) and
suppressed PRC (–40. 5 [–272.9 to –4.5] mIU/mL; P ¼ .002).
Effect of Short-Term and Long-Term Albumin
Treatment on Chemokines; Growth Factors; and
Biomarkers of Macrophage Activation,
Endothelial Dysfunction, and Coagulation/
Platelet Function (Pilot-PRECIOSA and INFECIR-
2 Studies)
To have a comprehensive view of the effects of albumin
treatment in both the Pilot-PRECIOSA and the INFECIR-2duced by treatment with HAlbD (blue color in all panels) and
IOSA Study. (A) Individual changes in serum albumin con-
a (serum albumin concentration < 34 g/L). The horizontal lines
. All 6 patients with hypoalbuminemia treated with HAlbD
oncentration up to normal levels, which persisted during the
ients with baseline hypoalbuminemia treated with LAlbD had
malized the serum albumin concentration. (B–D) Two factors
was the albumin dosage: among the 13 patients with baseline
um albumin was almost double in patients receiving HAlbD vs
mechanism by which baseline serum albumin concentration
ithout hypoalbuminemia, the inhibition of hepatic synthesis of
lbumin to abnormal levels during albumin treatment. (D) This
orrelation between the baseline serum albumin concentration
e lower the baseline levels of serum albumin, the higher the
min in both the LAlbD and HAlbD groups. (E) Circulatory
patients receiving LAlbD, with high peaks of PRA in 6 patients.
eceiving HAlbD, with only 1 patient presenting 1 peak of PRA
Figure 2. Changes in IL-6 and other cytokines induced by treatment with HAlbD (blue color in all panels) and LAlbD (red color)
in the 15 patients included in the Pilot-PRECIOSA study with sequential cytokines measurements. (A) The degree of systemic
inflammation, as estimated by repeated measurements of plasma IL-6 in baseline conditions and during treatment, was
extremely unstable in 4 patients receiving LAlbD and in 1 receiving HAlbD. (B) In the remaining patients, there was a marked
suppression of the circulating plasma levels of IL-6 (mainly in patients receiving HAlbD) or no change to minor changes (mainly
in patients receiving LAlbD). (C, D) Data derived from the assessment of a large panel of inflammatory cytokines at baseline
and at week 6 showed that plasma levels of IL-6, vascular endothelial growth factor, G-CSF, and IL-1 receptor antagonist had
a median reduction from baseline (interquartile range, %) that was significantly greater among patients treated with HAlbD than
among those receiving LAlbD. G-CSF, granulocyte colony-stimulating factor; IL1-ra, IL-1 receptor antagonist.
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LIVERstudies, we assessed a broad variety of soluble factors,
including chemokines, growth factors, and markers of
macrophage activation and endothelial and coagulation/
platelet dysfunction. As shown in Supplementary Tables 3
and 4, in both studies, albumin treatment was associated
with minor or no changes in most of these factors, sug-
gesting that it exerts its immunomodulatory effect mainly by
influencing production and/or release of specific cytokines.Discussion
Current albumin dosage in cirrhosis is based on empir-
ical assumptions and on the concept that albumin mainly
acts as a plasma volume expander.8 Of note, albumin ther-
apy can have many other important biological effects,
because it is able to bind to and inactivate a wide range ofendogenous and exogenous ligands.1 The ability of albumin
to bind proinflammatory molecules such as pathogen-
associated molecular patterns (e.g., the Gram-negative bac-
teria byproduct lipopolysaccharide),9 prostaglandins,10 ni-
tric oxide,11 and reactive oxygen and nitrogen species12
could be of great importance in the context of cirrhosis,
because these molecules are involved in the pathogenesis of
the systemic inflammation and circulatory and organ
dysfunction/failure that characterize decompensated
cirrhosis and ACLF.13 Because the occurrence of these non-
osmotic effects of albumin therapy in cirrhosis was elusive,
there was an urgent need to address this question, which
gave rise to the present study.
The current article describes 5 important and, to our
knowledge, previously unreported observations on the
pathophysiology and albumin treatment of decompensated
Table 2.Baseline Plasma Levels of Cytokines Among Healthy Individuals (HS), Patients From the Pilot-PRECIOSA (P-PR)









HS vs p-PR HS vs INF-2 p-PR vs INF-2
TNF-a
Median level (IQR), pg/mL 12.3 (11.5–16.9) 21.8 (16.0–30.6) 32.0 (21.9–49.8) .001 .0001 .04
Missing variable, n (%) 0 (0) 0 (0) 0 (0)
G-CSF
Median level (IQR), pg/mL 3.6 (2.4–5.7) 20.0 (8.8–156.9) 74.4 (32.0–155.5) .0008 .0001 .11
Missing variable, n (%) 0 (0) 1 (7) 17 (22)
IL-1ra
Median level (IQR), pg/mL 7.1 (3.8–13.2) 13.1 (9.1–32.8) 29.6 (8.3–76.5) .02 .0001 .26
Missing variable, n (%) 0 (0) 0 (0) 0 (0)
IL-6
Median level (IQR), pg/mL 0.9 (0.9–0.9) 10.5 (8.0–25.1) 37.1(22.6–107.6) .0001 .0001 .0001
Missing variable, n (%) 0 (0) 0 (0) 0 (0)
IL-10
Median level (IQR), pg/mL 1.1 (1.1–2.4) 2.7 (0.8–10.8) 10.9 (6.7–19.0) .20 .0001 .02
Missing variable, n (%) 0 (0) 3 (20) 13 (17)
IL-17A
Median level (IQR), pg/mL 0.7 (0.7–3.3) 17.7 (2.3–32.4) 3.2 (1.4–7.2) .0002 .002 .05
Missing variable, n (%) 0 (0) 3 (20) 0 (0)
IFNg
Median level (IQR), pg/mL 3.0 (2.2–4.7) 6.7 (2.1–35.8) 6.8 (1.5–18.4) .11 .04 .49
Missing variable, n (%) 0 (0) 0 (0) 0 (0)
VEGF
Median level (IQR), pg/mL 24.4 (14.7–45.2) 59.0 (26.3–230.7) 61.0 (32.1–183.0) .02 .002 .77
Missing variable, n (%) 0 (0) 1 (7) 32 (41)
G-CSF, granulocyte colony-stimulating factor; IFN, interferon; IL-1ra, IL-1 receptor antagonist; IQR, interquartile range; TNF,
tumor necrosis factor; VEGF, vascular endothelial growth factor.
aBold type indicates P < .05. Italic type indicates P ¼ .05.








cirrhosis. The first is that the long-term albumin dosage
required to normalize serum albumin concentration is much
higher than that used in the therapeutic RCTs so far per-
formed.4,14 Second, circulatory dysfunction is not a steady
state or a slowly progressive process, as it has been tradi-
tionally considered, but rather an extremely unstable con-
dition. Third, systemic inflammation in cirrhosis is also
unstable, with acute episodes of bursts of circulating cyto-
kines in the absence of any identifiable precipitating event.
Fourth, HAlbD, but not LAlbD treatment, is associated with
significant improvement in LV function in decompensated
cirrhosis, which is currently considered an important
mechanism of systemic circulatory dysfunction.15 Finally,
and most importantly, the sequential assessment of the
plasma levels of IL-6 during albumin treatment showed, for
the first time to our knowledge, that long-term albumin
treatment at high dosage has immunomodulatory effects in
decompensated cirrhosis. The transcendence of this last
finding was the reason to complete the study with 2 addi-
tional investigations. The first was aimed at assessing
whether the suppressive effect of albumin on IL-6 observed
in the patients included in the Pilot-PRECIOSA study also
extended to other cytokines and inflammatory molecules.
The second was aimed at investigating whether the immu-
nomodulatory effect observed during long-term treatmentwith HAlbD in patients without bacterial infection also oc-
curs after short-term (1 week) HAlbD treatment in patients
with bacterial infections. For these objectives, we leveraged
the availability of biobanking material from the Pilot-
PRECIOSA and INFECIR-2 studies.
The initial albumin dose evaluated in the Pilot-PRECIOSA
study (1 g/kg every 2 weeks for 12 weeks) was based on
that used in the pioneer RCT by Gentilini et al14 (25 g per
week) that explored the effect of long-term of albumin
treatment on the response to diuretics in patients with
cirrhosis ascites and in 2 RCTs that explored the long-term
effect of albumin administration on the natural course of
decompensated cirrhosis (the ANSWER study, 40 g of al-
bumin every week,4 and the MATCH study, 40 g of albumin
every 2 weeks16). The results of the current study indicate
that a dose of 1g/kg, which is higher than the MATCH study
dose and only slightly lower than the ANSWER study dose,
was clearly insufficient to normalize serum albumin con-
centration in 7 of the 8 patients with hypoalbuminemia
included in the LAlbD group. In contrast, our second albu-
min dosage (1.5 g/kg per week) rapidly normalized serum
albumin concentration in all patients with hypoalbuminemia
included in the HAlbD group.
The time-course changes of serum albumin concentra-
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LIVERfeedback mechanism by which hepatic albumin synthesis
is regulated by the serum albumin concentration17 is fully
operative in patients with advanced cirrhosis. Normali-
zation of serum albumin concentration in patients with
hypoalbuminemia receiving HAlbD occurred very rapidly
(within 2 weeks) after the onset of albumin treatment, but
once normalized, it remained within normal limits
throughout the study despite the weekly administration of
albumin at a concentration of 20 g/dL (5 times higher
than the normal serum albumin concentration). This rapid
and intense initial increase in serum albumin concentra-
tion was probably the consequence of the combination of
increased albumin synthesis by the liver secondary to
hypoalbuminemia and the effect of the exogenous albumin
administrations. In contrast, after normalization of serum
albumin, the inhibitory effect of normo-albuminemia on
albumin synthesis precluded any further increase in
serum albumin concentration, despite continuous albumin
treatment. The homeostatic feedback mechanism of serum
albumin would also explain why albumin treatment did
not increase serum albumin concentration in patients
without hypoalbuminemia. For additional explanatory
details, see Figure 1 legend.
The most relevant finding of our study was the
observation that both long-term and short-term albumin
treatment, if given at high dosage, are associated with
significant immunomodulatory effects in decompensated
cirrhosis. Three lines of evidence supported this conclu-
sion. The first derived from the sequential measurement
of IL-6 during albumin treatment in patients included in
the pilot-PRECIOSA study. The median reduction from
baseline of plasma IL-6 levels was significantly greater
among patients receiving HAlbD than among those
receiving LAlbD. This finding is important considering
that IL-6 has broad effects on immune and nonimmune
cells and often displays hormone-like characteristics that
can affect homeostatic processes.18 The second line of
evidence derived from the analysis of the effect of albumin
treatment on cytokines other than IL-6 in biobanking
material from the Pilot-PRECIOSA study. This investiga-
tion confirmed the observations of the first investigation.
Treatment with HAlbD, but not with LAlbD, was associ-
ated with significant decreases in plasma IL-6 during
treatment. Moreover, it showed that this effect also
involved other keystone cytokines (eg, granulocyte
colony-stimulating factor), confirming that long-term
therapy with HAlbD, but not with LAlbD, induces a sig-
nificant and extensive immunomodulatory effect in
decompensated cirrhosis. Finally, the third line of evi-
dence was obtained from the analysis of biobanking
plasma samples from the INFECIR-2 study. Treatment
with albumin plus antibiotics was associated with a rapid,
significant, and widespread suppression of the circulating
levels of cytokines, an effect not observed with antibiotics
alone. It was interesting to observe that the immuno-
modulatory effect of albumin in the Pilot-PRECIOSA and
INFECIR-2 studies was related mainly to the inhibitory
effect of albumin on cytokine production but not to an
effect on other inflammatory molecules.
Table 4.Effects of LAlbD and HAlbD Administration on Cardiovascular and Splanchnic Hemodynamics, Cardiac Peptides and
Standard Liver and Renal Function Parameters
LAlbD (n ¼ 10)
P
value
HAlbD (n ¼ 8)
P
valueBaseline Week 14 Baseline Week 14
Systemic hemodynamics n ¼ 7 n ¼ 8
RAP, mm Hg 6 (4–8) 4 (4–10) 0.87 8 (4–8) 9 (6–9) .26
MPAP, mm Hg 16 (15–17) 15 (12–20) 0.55 15 (11–18) 18 (15–25) .02
PCWP, mm Hg 10 (9–11) 8 (7–13) 0.74 11 (8–15) 12 (10–14) .11
Cardiac index, L/min/m2 3.9 (1.8–4.6) 3.8 (2.3–5.3) 0.09 4.2 (3.0–5.0) 5.3 (3.1–6.8) .04
Heart rate, bpm 61 (59–82) 75(62–86) 0.21 69 (59–91) 68 (62–76) .21
Systolic volume, mL 120 (40–127) 90 (52–135) 0.74 125 (85–145) 165 (110–190) .04
LV stroke work index, g$m/m2 48 (24–64) 44 (27–68) 0.74 54 (49–69) 82 (51–97) .04
SVRI, dyn$s/cm5/m2 1158 (1042–3840) 1182 (944–2762) 0.18 1257 (952–1693) 1072 (728–1183) .09
MAP, mm Hg 78 (63–88) 77 (75–85) 0.61 78 (74–85) 77 (66–84) .48
Cardiac peptides n ¼ 9 n ¼ 6
ANP, fmol/mL 58 (23–84) 53 (37–64) 0.59 41 (13–87) 65 (29–155) .14
BNP, pg/mL 82 (25–221) 37 (34–126) 0.45 41 (32–69) 49 (18–128) .46
Splanchnic hemodynamics n ¼ 7 n ¼ 6
FHVP, mm Hg 15 (9–17) 12 (5–17) 0.45 11 (8–14) 9 (5–10) .12
WHVP, mm Hg 35 (25–38) 30 (26–39) 0.67 32 (29–36) 28 (25–31) .21
HVPG, mm Hg 19 (15–20) 21 (14–22) 0.34 19 (17–27) 22 (18–25) .89
Liver and renal function n ¼ 10 n ¼ 8
AST, UI/L 58 (27–78) 53 (26–69) 0.15 45 (40–112) 34 (31–55) .02
ALT, UI/L 27 (19–46) 25 (16–34) 0.11 35 (28–56) 24 (21–39) .13
Serum creatinine, mg/dL 1.3 (1.0–1.4) 1.0 (0.9–1.3) 0.06 0.9 (0.8–1.3) 0.9 (0.7–1.2) .24
BUN, m/dL 26 (16–47) 22 (16–32) 0.16 20 (15–31) 24 (17–36) .25
Serum sodium, mEq/L 132 (126–136) 133 (129–137) 0.67 130 (129–135) 132 (131–134) .87
Serum albumin, g/L 27 (25–40) 35 (31–40) 0.06 27 (22–35) 40 (35–41) .03
Serum bilirubin, mg/dL 1.8 (1.0–2.1) 1.8 (1.1–2.8) 0.41 3.7 (1.9–13.0) 1.9 (1.6–16.8) .40
INR 1.3 (1.1–1.6) 1.5 (1.1–1.7) 0.29 1.4 (1.3–2.3) 1.4 (1.3–2.5) .46
Child-Pugh score, points 8 (6–10) 8 (7–9) 0.37 9 (8–11) 7 (6–8) .02
MELD score, points 14 (11–17) 14 (9–17) 0.59 16 (13–26) 16 (13–27) .25
ALT, alanine aminotransferase; ANP, atrial natriuretic peptide; AST, aspartate aminotransferase; BNP, brain natriuretic peptide;
BUN, blood urea nitrogen; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient; LV, left ventricular;
MAP, mean arterial pressure; MELD, model for end stage liver disease; MPAP, mean pulmonary artery pressure; PCWP,
pulmonary capillary wedge pressure; RAP, right atrial pressure; SVRI, systemic vascular resistance index; WHVP, wedge
hepatic venous pressure.
NOTE. Values are reported as median (interquartile range). Normal value ranges are as follow: right atrial pressure, 2–10 mm
Hg; mean pulmonary arterial pressure, 10–25 mm Hg; pulmonary capillary pressure, 6–14 mm Hg; cardiac index, 2.5–4 L/min/
m2; SV, 60–100 mL; LV stroke work index, 45–75 g$m/m2/beat; SVRI, 1970–2390 dyn$sec/cm5/m2; MAP, 80–95 mm Hg;
ejection fraction, >50%; ANP, 9–24 fmol/mL; BNP, 4–37 pg/mL; HVPG, 1–5 mm Hg.
aBold type indicates P < .05.








An intriguing finding of our study was the observation of 1
or 2 acute, intense, and spontaneously reversible peaks of
PRA and plasma IL-6 during albumin treatment in many pa-
tients included in the Pilot-PRECIOSA study. There are rea-
sons to suggest that the prevalence and frequency of these
peaks in the current study are not representative of their
actual prevalence and frequency in patients with decom-
pensated cirrhosis. First, we monitored PRA and plasma IL-6
only once every week or every 2 weeks during the study
period. However, according to our data, the duration of these
peaks may range from less than 1 to 2 or more weeks.
Therefore, we could have lost a significant number of peaks in
our patients. Interestingly, the prevalence of PRA and IL-6
peaks was lower in patients receiving HAlbD than in those
receiving LAlbD, suggesting that treatment with HAlbD may
prevent the occurrence of these acute episodes of aggravationof circulatory dysfunction and systemic inflammation in
decompensated cirrhosis. Although the current study is, to
our knowledge, the first to show these abnormalities, the
existence of such episodes of acute circulatory impairment
and systemic inflammation had already been anticipated by
the systemic inflammation hypothesis as an explanation for
the 40% prevalence of ACLF in patients without any identi-
fiable exogenous precipitating event of the syndrome.13,19 The
proposed mechanism of such changes by the systemic
inflammation hypothesis is the existence of transient bursts of
translocation of viable bacteria or bacterial products from the
intestinal lumen to the systemic circulation. Therefore, the
potential futility of single measurements of renin and cyto-
kines as surrogate markers of effective blood volume and
systemic inflammation in patients with decompensated
cirrhosis has to be considered in the design of future studies.
Table 5.Baseline Plasma Levels of Cytokines and Their Changes During the First Week of Treatment, in Patients From the INFECIR-2 Study Who Were Randomly Assigned















































TNF-a 0 (0) 37.9 (23.3 to 50.0) –2.8 (–12.6 to 3.2) –8.2 (–28.9 to 11.9) .05 .01 0 (0) 31.1 (21.2 to 45.3) –3.4 (–14.7 to 3.1) –16.2 (–40.5 to 12.8) .01 .04
G-CSF 9 (23) 74.4 (19.2 to 185.5) –3.4 (–55.3 to 11.5) –21.2 (–91.4 to 21.5) .33 .85 8 (21) 73.5 (33.6 to 115.0) –41.5 (–65.1 to 8.4) –58.6 (–88.8 to 30.2) .01 .01
IL-1ra 0 (0) 29.6 (8.3 to 71.5) –0.6 (–28.0 to 9.0) –5.9 (–51.5 to 23.6) .37 .31 0 (0) 29.9 (8.3 to 76.5) –0.5 (–34 to 2.1) –3.5 (–73.0 to 8.3) .05 .28
IL-6 0 (0) 37.7 (18.3 to 94.7) –7.0 (–19.9 to 20.7) –14.8 (–43.5 to 66.4) .53 .27 0 (0) 36.9 (23.9 to 158.9) –7.7 (–33.1 to 0.3) –23.0 (–55.0 to 3.8) .003 .005
IL-10 8 (20) 10.7 (6.3 to 20.9) –0.2 (–6.7 to 4.4) –1.8 (–56.7 to 50.1) .74 .99 5 (13) 11.0 (6.7 to 15.1) –1.5 (–7.6 to 2.8) –15.6 (–53.5 to 63.0) .03 .03
IL-17A 0 (0) 3.7 (1.2 to 8.2) 0.1 (–1.7 to 1.3) 2.5 (–38.6 to 81.1) .92 .99 0 (0) 2.7 (1.6 to 7.2) –0.5 (–2.7 to 0.4) –15.4 (–52.4 to 29.9) .05 .09
IFNg 0 (0) 4.8 (1.2 to 15.6) –0.2 (–6.2 to 1.3) –7.9 (–51.7 to 37.1) .17 .52 0 (0) 8.4 (2.0 to 19.7) –0.5 (–8.6 to 4.3) –24.8 (–63.3 to 52.9) .48 .24
VEGF 16 (40) 65.4 (45.6 to 204.0) –18.5 (–41.4 to 18.2) –16.4 (–45.3 to 29.4) .30 .31 16 (42) 50.6 (24.1 to 183.0) –13.9 (–49.0 to 11.9) –24.7 (–36.9 to 32.5) .10 .29
NOTE. Changes during the first week of albumin treatment were assessed between day 3 and day 7 after inclusion. There were no significant between-group differences in
cytokine levels at baseline.
G-CSF, granulocyte colony-stimulating factor; IFN, interferon; IL-1ra, IL-1 receptor antagonist; IQR, interquartile range; TNF, tumor necrosis factor; VEGF, vascular
endothelial growth factor.
















Although circulatory dysfunction in cirrhosis has been
traditionally attributed to splanchnic arterial vasodilation,
there is now evidence that impairment in LV function also
plays a major role. In fact, the cardiac index in cirrhosis falls
progressively from compensated cirrhosis to decom-
pensated cirrhosis and HRS.15 Our data show that normal-
ization of serum albumin concentration with long-term
HAlbD treatment in noninfected patients with decom-
pensated cirrhosis does not induce significant changes in
central blood volume and portal pressure. However, it was
associated with a significant improvement in LV function.
These observations are important for 2 reasons. First, they
explain why treatment with HAlbD is generally not associ-
ated with variceal bleeding or pulmonary edema in
decompensated cirrhosis without bacterial infections. Sec-
ond, because systemic inflammation induces direct delete-
rious effect on heart function, our study supports the
concept that the beneficial effect of albumin treatment in the
management of organ dysfunction/failure in cirrhosis may
be mediated, at least in part, by its immunomodulatory ef-
fect. In fact, this has also been observed in rats with carbon
tetrachloride-induced cirrhosis, which develop evidence of
systemic inflammation and inflammation in the cardiac tis-
sue associated with severe impairment of LV contractibility,
which reverses after albumin treatment.20
One of the strengths of our study is the use of multiple
plasma samples, the prospective collection of which was
prespecified in the context of 2 well-designed multicenter
controlled trials, 1 of which was randomized. A limitation of
our study was the relatively low number of patients
included in the Pilot-PRECIOSA study. However, the most
important finding of this investigation, the significant
immunomodulatory effect of albumin treatment in patients
with advanced cirrhosis, was confirmed by assessing the
effect of albumin treatment on a large panel of inflammatory
cytokines, both in patients included in the Pilot-PRECIOSA
study and in a relatively large number of patients
included in the INFECIR-2 study, thus offering solid addi-
tional arguments supporting our conclusions.
In summary, the current study allowed us to uncover
important findings related to the efficacy of albumin treat-
ment in cirrhosis. The most outstanding were that high
doses of albumin, but not low doses of albumin, in patients
with decompensated cirrhosis have significant immuno-
modulatory effects, prevent a phenomenon shown by the
present study that consists of bursts of circulatory
dysfunction, improve LV function, and correct serum albu-
min levels without inducing albumin overdose, probably
because of the preservation of negative feedback mecha-
nisms controlling albumin synthesis, even in advanced liver
disease. Because albumin is capable of binding to and
inactivating many inflammatory promoters, such as
pathogen-associated molecular patterns, bioactive lipid
metabolites, reactive oxygen species, and nitric oxide, the
immunomodulatory effects of albumin could be related to
this scavenging function. However, this explanation may be
too simplistic, and further investigations are clearly needed
to understand the anti-inflammatory effect of albumin
treatment in cirrhosis.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
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